Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Revelation Biosciences ( (REVB) ) has provided an announcement.
On October 15, 2025, Revelation Biosciences announced the adjournment of its Special Meeting of Stockholders to October 29, 2025, due to insufficient shares present for a quorum. The company encourages all stockholders to participate and vote, emphasizing the importance of their involvement in the decision-making process.
The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. The company is involved in multiple programs to evaluate Gemini, including as a prevention for post-surgical infection, acute kidney injury, and for the treatment of chronic kidney disease.
Average Trading Volume: 428,918
Technical Sentiment Signal: Sell
Current Market Cap: $3.13M
Find detailed analytics on REVB stock on TipRanks’ Stock Analysis page.